Ashiq Masood, MD
Hematology & Oncology · Indianapolis, INNPI 1225260110
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,686 of the $12,345 with a category attached, or 94.7%. 3 manufacturers reported payments, led by Boehringer Ingelheim at 59.4% of the total. Reporting peaked in 2019 at $7,336 and has fallen 99.4% since, to $43 in 2025.
Across 4 payments — averaging $3086.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$7K
- Ipsen Biopharmaceuticals, Inc$5K
- AstraZeneca$43
Across 68 payments — averaging $4916.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$129K
- AbbVie$76K
- Genentech, Inc.$48K
- Novocure Inc.$44K
- Ipsen Bioscience Inc.$38K
What the payments were for
- Speaking & faculty fees$11,68695%
- Travel & lodging$6165%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $7,336 |
| Ipsen Biopharmaceuticals, Inc | 2 | $4,966 |
| AstraZeneca | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,345 in reported general payments places this provider in the 65th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 11 | $28,439 |
| Potassium Chloride | 26 | $366 |
| Ondansetron Hcl | 16 | $288 |
| Olanzapine | 11 | $163 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Indianapolis
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
- Amro ElshouryIndianapolis$212K
- Brian MulherinIndianapolis$175K
- Muhammad Sarfraz NawazIndianapolis$172K
- John EdwardsIndianapolis$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.